AZN - At JPM Alexion gives preview of what AstraZeneca is getting after shelling out $39B

After AstraZeneca ([[AZN]] -0.6%) splashed out $39B for Alexion ([[ALXN]] -0.4%) to expand its immunology presence, the transaction paved way for naturally following questions about whether it was justified. Now, ALXN has offered up some more information about what, exactly, the AZN is getting for its money.Alexion’s sales checked in at ~$5.9B in 2020, up 18.7% year over year. For 2025, the company is targeting about $9B-$10B. To hit that goal, Alexion’s counting on significantly expanding the number of U.S. neurology patients receiving its drugs.In 2020, Soliris grew its neurology patient count in generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) to 2,588 in the U.S. from 1,885 the prior year. By 2025, it intends to reach 7,500 patients. A key part of that expansion goal rests on Soliris follow-up Ultomiris. Phase 3 data from Ultomiris in gMG and NMOSD are expected to read out in 2H of 2021 and 2H of 2022, respectively.Alexion

For further details see:

At JPM Alexion gives preview of what AstraZeneca is getting after shelling out $39B